DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 74 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Akums Drugs and Pharmaceuticals share price: Good Buy After Q1 FY27 Results?

Univest 2 hrs ago·7 Sept 2026, 7:10 am

Akums Drugs and Pharmaceuticals has reported its financial results for the first quarter of the fiscal year 2027. The company's performance in this period is being closely watched by the market to gauge its operational efficiency and growth trajectory.

For investors, the key takeaway is the company's ability to maintain its momentum in a competitive pharmaceutical landscape. The results provide insight into the demand for its products and the effectiveness of its cost management strategies, which are critical for sustaining profitability.

Moving forward, investors should monitor the company's guidance for the remainder of the year and any updates on its expansion plans. These factors will be important in determining the stock's potential for further growth.